Levi & Korsinsky, LLP announces that a ATHA class action lawsuit has been filed on behalf of investors who purchased Athira Pharma, Inc. (ATHA) Athira Pharma, Inc. securities between September 18, 2020 and June 17, 2021 and/or purchased common stock of Athira in or traceable to the Company’s registration statement issued in connection with the Company’s September 2020 initial public offering priced at $17.00 per share.. For more on the ATHA Lawsuit please contact us today.
According to the Athira Pharma, Inc. lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that:
(1) the research conducted by Defendant Kawas, which formed the foundation for Athira’s product candidates and intellectual property, was tainted by Kawas’ scientific misconduct, including the manipulation of key data through the altering of Western blot images; and (2) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and omitted material facts necessary in order to make the statements made not misleading.
If you suffered a loss in Athira Pharma, Inc. you have until August 24, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.